Anygen Overview
- Founded
-
2000
- Status
-
Public
- Employees
-
112
- Stock Symbol
-
196300
- Share Price
-
$6.77
- (As of Friday Closing)
Anygen General Information
Description
AnyGen Co Ltd is a bio-venture company. The Company manufactures peptide APIs and new drug development. It offers GMP peptides, Generic peptides, Custom peptides, Catalog peptides and other services.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Primary Office
- Gwangju Techno Park Test Production Building
- Suite 206
- Gwangju, 61008
- South Korea
+82 000-000-0000
Anygen Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.77 | $6.49 | $6.46 - $26.07 | $37.9M | 5.6M | 16.2K | -$0.32 |
Anygen Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 57,044 | 74,184 | 69,945 | 47,287 |
| Revenue | 10,191 | 8,963 | 7,213 | 5,383 |
| EBITDA | 1,495 | 1,943 | 1,069 | (3,000) |
| Net Income | (1,749) | (1,475) | (2,085) | (5,698) |
| Total Assets | 25,599 | 27,239 | 28,633 | 26,531 |
| Total Debt | 6,690 | 6,740 | 12,992 | 9,135 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Anygen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anygen Patents
Anygen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3121195-A1 | Novel exenatide analogue and use thereof | Granted | 21-Mar-2014 | 0000000000 | |
| EP-3121195-B1 | Novel exenatide analogue and use thereof | Active | 21-Mar-2014 | 000000000 | |
| EP-3121195-A4 | Novel exenatide analogue and use thereof | Granted | 21-Mar-2014 | 000000000 | 0 |
| US-20170128541-A1 | Novel exenatide analogue and use thereof | Granted | 21-Mar-2014 | 000000000 | 0 |
| US-11103557-B2 | Exenatide analogue and use thereof | Active | 21-Mar-2014 | C07K14/605 | 00 |
Anygen Executive Team (5)
Anygen Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Chang Hwan Kim | Anygen | Executive Managing Director & Board Member | 000 0000 |
| Jae Il. Kim Ph.D | Anygen | Chief Executive Officer & Board Member | 000 0000 |
| Joo-yol Choi | Hyundai Venture Investment Corporation | Board Member | 000 0000 |
| Sam Sik Kim | Self | Board Member | 000 0000 |
| Young Joon Kim | Anygen | Board Member & Director of Research & Development | 000 0000 |
Anygen Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
